JP2008531594A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008531594A5 JP2008531594A5 JP2007557195A JP2007557195A JP2008531594A5 JP 2008531594 A5 JP2008531594 A5 JP 2008531594A5 JP 2007557195 A JP2007557195 A JP 2007557195A JP 2007557195 A JP2007557195 A JP 2007557195A JP 2008531594 A5 JP2008531594 A5 JP 2008531594A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- weight
- amount
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 43
- -1 N-ethyl-carbamoyloxy Chemical group 0.000 claims 14
- 238000000034 method Methods 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 11
- 230000036470 plasma concentration Effects 0.000 claims 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 8
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 7
- 235000021355 Stearic acid Nutrition 0.000 claims 7
- 239000000945 filler Substances 0.000 claims 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 7
- 239000008117 stearic acid Substances 0.000 claims 7
- 208000024827 Alzheimer disease Diseases 0.000 claims 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 5
- 229930195725 Mannitol Natural products 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 5
- 239000000314 lubricant Substances 0.000 claims 5
- 239000000594 mannitol Substances 0.000 claims 5
- 235000010355 mannitol Nutrition 0.000 claims 5
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 5
- 239000000454 talc Substances 0.000 claims 5
- 229910052623 talc Inorganic materials 0.000 claims 5
- MTVWFVDWRVYDOR-UHFFFAOYSA-N 3,4-Dihydroxyphenylglycol Chemical compound OCC(O)C1=CC=C(O)C(O)=C1 MTVWFVDWRVYDOR-UHFFFAOYSA-N 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 4
- 239000011230 binding agent Substances 0.000 claims 4
- 239000007884 disintegrant Substances 0.000 claims 4
- 238000005567 liquid scintillation counting Methods 0.000 claims 4
- 235000019359 magnesium stearate Nutrition 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 3
- 239000008187 granular material Substances 0.000 claims 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 3
- 238000005550 wet granulation Methods 0.000 claims 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 102000010909 Monoamine Oxidase Human genes 0.000 claims 2
- 108010062431 Monoamine oxidase Proteins 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims 1
- 206010036631 Presenile dementia Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000004558 lewy body Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000003068 static effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65647705P | 2005-02-24 | 2005-02-24 | |
| PCT/US2006/006636 WO2006091836A1 (en) | 2005-02-24 | 2006-02-24 | Formulations of ladostigil tartrate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008531594A JP2008531594A (ja) | 2008-08-14 |
| JP2008531594A5 true JP2008531594A5 (enExample) | 2009-03-05 |
Family
ID=36927766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007557195A Withdrawn JP2008531594A (ja) | 2005-02-24 | 2006-02-24 | 酒石酸ラドスチジルの製剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8022104B2 (enExample) |
| EP (1) | EP1848417A1 (enExample) |
| JP (1) | JP2008531594A (enExample) |
| AU (1) | AU2006216509B8 (enExample) |
| CA (1) | CA2600603A1 (enExample) |
| IL (1) | IL185420A0 (enExample) |
| WO (1) | WO2006091836A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2600603A1 (en) * | 2005-02-24 | 2006-08-31 | Teva Pharmaceutical Industries Ltd. | Formulations of ladostigil tartrate |
| WO2007038677A2 (en) * | 2005-09-28 | 2007-04-05 | Teva Pharmaceutical Industries Ltd. | Methods for preparation of ladostigil tartrate crystalline form a1 |
| EP1954667B1 (en) * | 2005-11-17 | 2017-02-08 | Teva Pharmaceutical Industries Ltd | Methods for isolating propargylated aminoindans |
| US20070135518A1 (en) * | 2005-12-09 | 2007-06-14 | Marta Weinstock-Rosin | Use of low-dose ladostigil for neuroprotection |
| EP1956904B1 (en) * | 2005-12-09 | 2017-04-12 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Low-dose ladostigil for the treatment of mild cognitive impairment |
| TW200744576A (en) * | 2006-02-24 | 2007-12-16 | Teva Pharma | Propargylated aminoindans, processes for preparation, and uses thereof |
| US20070232691A1 (en) * | 2006-03-31 | 2007-10-04 | Tamar Goren | Use of ladostigil for the treatment of schizophrenia |
| WO2012059920A1 (en) * | 2010-11-02 | 2012-05-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Ladostigil dosage regime |
| EP2811995B1 (en) | 2012-02-12 | 2017-08-09 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Ladostigil therapy for immunomodulation |
| WO2013182625A1 (en) * | 2012-06-08 | 2013-12-12 | Actavis Group Ptc Ehf | Pharmaceutical formulation with propargylamine compound |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1534864A (en) * | 1919-12-19 | 1925-04-21 | Hazel Atlas Glass Co | Apparatus for tempering glassware |
| US2026165A (en) * | 1934-08-01 | 1935-12-31 | Libbey Owens Ford Glass Co | Process and apparatus for producing case hardened glass |
| US3903297A (en) | 1973-11-01 | 1975-09-02 | Upjohn Co | Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs |
| US4086263A (en) * | 1976-11-17 | 1978-04-25 | Ppg Industries, Inc. | Shipping rack having spacer strips attached thereto |
| US4488192A (en) * | 1982-05-28 | 1984-12-11 | International Business Machines Corporation | Cooling arrangement for hermetically sealed disk files |
| US5744500A (en) | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| IL92952A (en) | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
| AU1867095A (en) | 1994-01-10 | 1995-08-01 | Technion Research & Development Foundation Ltd. | 1-aminoindan derivatives and compositions thereof |
| FI100397B (fi) * | 1995-10-24 | 1997-11-28 | Glassrobots Oy | Lämmönsiirtomenetelmä lasilevyjen taivutusuunissa ja taivutusuuni |
| US6053011A (en) * | 1996-03-21 | 2000-04-25 | Lisec; Peter | Process and plant for hardening glass plates |
| FR2747112B1 (fr) * | 1996-04-03 | 1998-05-07 | Commissariat Energie Atomique | Dispositif de transport d'objets plats et procede de transfert de ces objets entre ledit dispositif et une machine de traitement |
| DE69725467T2 (de) | 1996-12-18 | 2004-07-22 | Teva Pharmaceutical Industries Ltd. | Phenylethylamin-derivate |
| US6251938B1 (en) | 1996-12-18 | 2001-06-26 | Teva Pharmaceutical Industries, Ltd., | Phenylethylamine derivatives |
| DE69732984T2 (de) | 1996-12-18 | 2006-02-16 | Teva Pharmaceutical Industries Ltd. | Aminoindanderivate |
| CA2276150A1 (en) | 1996-12-30 | 1998-07-09 | Steven D. Young | Inhibitors of farnesyl-protein transferase |
| JPH1179388A (ja) * | 1997-09-16 | 1999-03-23 | Mitsui Eng & Shipbuild Co Ltd | ガラス類枚葉処理装置 |
| JPH1179389A (ja) * | 1997-09-16 | 1999-03-23 | Mitsui Eng & Shipbuild Co Ltd | 基板ガラス検査加工システム |
| TW444275B (en) * | 1998-01-13 | 2001-07-01 | Toshiba Corp | Processing device, laser annealing device, laser annealing method, manufacturing device and substrate manufacturing device for panel display |
| CA2477218A1 (en) | 2002-02-27 | 2003-09-04 | Teva Pharmaceutical Industries, Ltd. | Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective mao inhibitors |
| US20040010038A1 (en) | 2002-02-27 | 2004-01-15 | Eran Blaugrund | Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors |
| GB0322140D0 (en) * | 2003-09-22 | 2003-10-22 | Pfizer Ltd | Combinations |
| EP1686973A4 (en) | 2003-11-25 | 2009-03-25 | Technion Res & Dev Foundation | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DISEASES |
| US20050267076A1 (en) | 2004-05-14 | 2005-12-01 | Johns Hopkins University | Method for improving cognitive function |
| CA2600603A1 (en) | 2005-02-24 | 2006-08-31 | Teva Pharmaceutical Industries Ltd. | Formulations of ladostigil tartrate |
| EP1848689A1 (en) | 2005-02-24 | 2007-10-31 | Teva Pharmaceutical Industries Ltd. | Crystals of ladostigil tartrate, methods of production and pharmaceutical compositions thereof |
| US20060276537A1 (en) | 2005-06-01 | 2006-12-07 | Tamar Goren | Use of ladostigil for the treatment of multiple sclerosis |
| EP1956904B1 (en) | 2005-12-09 | 2017-04-12 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Low-dose ladostigil for the treatment of mild cognitive impairment |
| US20070135518A1 (en) | 2005-12-09 | 2007-06-14 | Marta Weinstock-Rosin | Use of low-dose ladostigil for neuroprotection |
| TW200744576A (en) | 2006-02-24 | 2007-12-16 | Teva Pharma | Propargylated aminoindans, processes for preparation, and uses thereof |
| US20070232691A1 (en) | 2006-03-31 | 2007-10-04 | Tamar Goren | Use of ladostigil for the treatment of schizophrenia |
-
2006
- 2006-02-24 CA CA002600603A patent/CA2600603A1/en not_active Abandoned
- 2006-02-24 WO PCT/US2006/006636 patent/WO2006091836A1/en not_active Ceased
- 2006-02-24 JP JP2007557195A patent/JP2008531594A/ja not_active Withdrawn
- 2006-02-24 AU AU2006216509A patent/AU2006216509B8/en not_active Ceased
- 2006-02-24 US US11/361,379 patent/US8022104B2/en not_active Expired - Fee Related
- 2006-02-24 EP EP06721040A patent/EP1848417A1/en not_active Withdrawn
-
2007
- 2007-08-21 IL IL185420A patent/IL185420A0/en unknown
-
2011
- 2011-08-17 US US13/211,721 patent/US20110301234A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11648232B2 (en) | Methods and compositions for treating excessive sleepiness | |
| CN107921032B (zh) | 用于治疗神经学疾病或病症的vmat2抑制剂 | |
| JP2018501299A5 (enExample) | ||
| JPH0757727B2 (ja) | 抑うつ障害の治療用に適した制御放出製薬組成物 | |
| JP2020534305A5 (enExample) | ||
| TW202011963A (zh) | Vmat2抑制劑化合物、組合物及其相關方法 | |
| KR20190072561A (ko) | 카바모일 페닐알라닌올 화합물 및 이의 용도 | |
| JP2008531594A5 (enExample) | ||
| TWI491395B (zh) | 一種內含用以治療神經退化性疾病之立即釋出與長效釋出藥物的口服劑量配方 | |
| JP2005508872A5 (enExample) | ||
| AU2006216509B2 (en) | Formulations of ladostigil tartrate | |
| HUP0200655A2 (hu) | Osanetant alkalmazása kedélyállapot-rendellenességek kezelésére használható gyógyszerek előállítására | |
| CN102188414A (zh) | 去氢厄弗酚在制备具有抗焦虑作用药物中的应用 | |
| TW200920348A (en) | Combination of picotamide with nafronyl | |
| HUP0103834A2 (hu) | Eljárás az acetil-kolin-szint növelésére | |
| AU2024278948A1 (en) | Solriamfetol for treating cognitive impairment in a subject with impaired cognition associated with obstructive sleep apnea and excessive daytime sleepiness | |
| WO2024249560A1 (en) | Solriamfetol for treating cognitive impairment in a subject with impaired cognition associated with obstructive sleep apnea and excessive daytime sleepiness | |
| JPWO2020247603A5 (enExample) | ||
| KR20240070564A (ko) | 알츠하이머병 예방 또는 치료용 약학적 조성물 | |
| WO2025099182A1 (en) | Induction regime for the administration of 2-(2-chlorphenyl)-2-(methylamino) cyclohexan-1-one | |
| JP2006083074A (ja) | 血中脂質低下剤 | |
| WO2007105286A1 (ja) | 血中脂質低下剤 | |
| CN104324026A (zh) | 一种抗焦虑的药物组合物及其应用 |